Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Jefferies London Healthcare Conference 2023
37 slides from Jb Chemicals & Pharmaceuticals's conference presentation, Nov 13, 2023
Slide 1: Exchange filing cover letter
November 13, 2023 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Stock Symbol: JBCHEPHARM Dear Sir, Subject: Presentation Enclosed please find the presentation proposed to be made by the Company at the Jef
Slide 2: JB Pharma – Jefferies London Healthcare Conference
JB Pharma (JB Chemicals & Pharmaceuticals Ltd) NSE : JBCHEPHARM BSE : JBCHEPHARM Jefferies London Healthcare Conference Nov 14th to 16th, 2023 www.jbpharma.com jbpharma/
Slide 3: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 4: JB Pharma at a glance
Synergistic acquisitions Peak productivity Domestic outperformer Jp) 24-26% Operating margin guidance Consistency of delivery Strong FCF for 0000 HEATH Dosage forms Gi leader Global regulatory approvals Medicated/Herbal lozenges & Leadership _ Key therapies Pillar Brands “J B PHARMA *° Dosage forms
Slide 5: Top 5 and key facts
46 8 40+ Top 5 Regulated/semi-regulated Global manufacturer of Years of operations with Multi-dosage formulation plants markets of presence through medicated/herbal lozenges consistent track record across with key global approvals/ direct operations and representing a substantial multiple businesses
Slide 6: Corporate Snapshot – Financial Overview
Corporate Snapshot – Financial Overview Revenue (INR mn) PAT (INR mn) ^Op EBITDA Margin (%) ROE (%) ROCE (%) 42% 27.4% 25.0% 24.3% 21.3% 31,490 29% 18.6% 15.4% 24,240 24% 22%# 21% 20,430 25% 16,430 17,750 15% 14,130 19% 18% 17% 13% 4,489 3,860 4,100 1,940 2,720 10% 1,385 FY18 FY19 FY20 FY21 FY22 FY2
Slide 7: Business Segments
Business Segments Total: INR 31490 mn* CAGR: 27% CAGR: 17% 16400 15090 11730 11270 12360 8920 9440 7970 FY20 FY21 FY22 FY23 Domestic International FY20 FY21 FY22 FY23 International CDMO API Formulations 6 • As of FY23 All figures in INR million
Slide 8: Increased Thrust on the Domestic and CDMO business
Increased Thrust on the Domestic and CDMO business Increased contribution of Domestic and CDMO segments which are high operating margins and ROCE businesses Increasing Share of the Domestic Revenue Increasing share of Domestic Formulations and CDMO** in the total business 45% 45% 41% 35% 54% 56% 51%
Slide 9: State of the Art Manufacturing Facilities
State of the Art Manufacturing Facilities 8 40+ 10 State of the Art Global Dosage forms manufacturing Regulatory produced facilities Accreditations Tablets Capsules Liquids IV Ampules Infusions Vials Ointments Cold Lozenges Sips Rubs 8
Slide 10: Facilities Details – Accreditations and Approvals
Facilities Details – Accreditations and Approvals Daman, India Panoli, India EU GMP US FDA WHO GMP EU GMP MHRA UK WHO GMP TGA - Australia MoH Ukraine SAHPRA MoH Russia 9
Slide 11: Facilities Details – Technologies and Systems
Facilities Details – Technologies and Systems OROS LIMS Semi permeable membrane Streamlining the Laser drilled hole Laboratory functions and database maintenance SCADA EBRM Minute by Minute Audit trail of critical Electronic Batch Record manufacturing processes Management 10
Slide 12: India Business
@® = India Business
Slide 13: Domestic Business: Stellar Growth over the years
Domestic Business: Stellar Growth over the years CAGR:27% 16400 11730 8920 40% 7970 FY20 FY21 FY22 FY23 INR millions 12
Slide 14: JB continues as one of the fastest growing companies
JB continues as one of the fastest growing companies, maintaining a market beating performance Among top 25, JB is the Fastest growing company fastest growing pharma Leadership position among the Top 25 in the IPM as company in the IPM in the covered markets per IQVIA MAT Sept’23 data 18% Vs IPM gro
Slide 15: Consistently Outperforming the Indian Pharmaceuticals Market
Consistently Outperforming the Indian Pharmaceuticals Market JB Pharma consistently outperforming IPM growth 27% #23 22% 20% 20% 18% 11% #25 MAT Mar’23 8% 5% #34 MAT Mar’21 FY20 FY21 FY22 FY23 IPM JB Pharma MAT Mar’20 Consistent Rank Improvement 14
Slide 16: JB Pharma: 15th largest company in IPM by Prescriptions
JB Pharma : 15th largest company in IPM by Prescriptions JB Pharma Total Prescriptions (in millions) 2 brands among the top 10 15680 most prescribed brands in the 12310 country 9290 Prescriptions growing at 3 year FY21 FY22 FY23 CAGR of 30% 15
Slide 17: Strong Prescriber Connect across Specialities
Strong Prescriber Connect across Specialities 128,000 Physicians 8,000 Cardiologists 46,000 Dentists 3,400 Nephrologists 23,000 Gynaecologists 3,200 Gastroenterologists 20,000 Pediatricians 11,500 Surgeons 16 All data as per IQVIA
Slide 18: Consistent Rank Improvement in the Top 6 brands
Consistent Rank Improvement in the Top 6 brands MAT Sept’22 Value Sales* MAT Sept’23 Value Sales* MAT Sept’22 Rank MAT Sept’23 Rank CILACAR 2920 3580 #48 #35 RANTAC 3140 3550 #41 #37 METROGYL 1730 2010 #149 #146 NICARDIA 1200 1620 #218 #157 CILACAR-T 1220 1520 #212 #172 AZMARDA 900 1070 - #297 17 Al
Slide 19: Building Stronger Brand Franchises
Building Stronger Brand Franchises INR 3900 INR 5800 INR 3260 INR 4120 INR 2240 INR 3010 mnSept’21 IQVIA MAT mnSept’23 IQVIA MAT mnSept’21 IQVIA MAT mnSept’23 IQVIA MAT mnSept’21 IQVIA MAT mn Sept’23 IQVIA MAT CILACAR T RANTAC DOM METROGYL P CILACAR M RANTAC MPS METROGYL DG CILACAR TC RANTAC RD METR
Slide 20: Productivity Led by Strong Execution: Consistent PCPM Improvement
Productivity Led by Strong Execution: Consistent PCPM Improvement Constant improvement in PCPM# Constant improvement in PCPM# Strong field force of 2500+ of medical reps 0.62 PCPM stands at INR 0.62 million at the end of 0.54 FY23, up from INR 0.36 million in FY20, registering 0.46 a strong growth o
Slide 21: JB Chronic Portfolio Outperforming the Industry
JB Chronic Portfolio Outperforming the Industry #20 JB Pharma’s Chronic Portfolio Outperforming the IPM #21 25%* #25 12% * 10%* IPM Growth% IPM Chronic Portfolio JB Pharma Chronic Growth% Portfolio Growth% MAT Sept’21 MAT Sept’22 MAT Sept’23 As per IQVIA MAT Sept’23 data vs MAT Sept’22 numbers, JB n
Slide 22: Top 10 in the Cardiac Therapy
JB Pharma now ranks amongst the Top 10 in the Cardiac Therapy; 3 brands among in the top 25 in Cardiology segment MAT MAR'21 MAT MAR'22 MAT MAR'23 #08 4 4 4 40 30 20 #13 MAT Mar’23 47 32 23 #14 MAT Mar’22 3 brands in Top 25 in the Cardiology segment MAT Mar’21 Addition of progressive and strong Gain
Slide 23: Growth Further Fuelled by Acquisitions
Growth Further Fuelled by Acquisitions Completed 4 acquisitions in CY22 deploying INR 13140 million Sanzyme • Marked JB’s entry into the high growth Azmarda • High growth, specialty focused brand in Portfolio probiotics segment the fast- growing Heart Failure segment • Complementary fit with JB’s st
Slide 24: Growth Further Fuelled by Acquisitions
Growth Further Fuelled by Acquisitions Stellar performance in all the acquired portfolios Sanzyme • Sporlac brand inching towards INR 1000 Azmarda • The brand continues to capture 16-18% of Portfolio million brand, up from INR 580 million pre total Sacubitril + Valsartan market in India acquisition
Slide 25: International Business
® International Business
Slide 26: International Business
International Business International Formulations CDMO • Direct Presence in Russia and South Africa • Among the top 5 manufacturers of Lozenges across the globe • Services the US generics market through an asset-light distributor model • Partnerships with some of the largest consumer healthcare bran
Slide 27: International Business: Stellar Growth across all businesses
International Business: Stellar Growth across all businesses International Export Formulations CDMO API 860 910 940 4060 10090 720 8170 8920 6960 2240 2530 1760 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 As a percentage to overall 67% 27% 6% International business revenue in FY 23 E
Slide 28: CDMO business a focus area
Besides domestic business, the CDMO business also one of the focus areas for the organization 60% Consistent Growth in the CMO Business Coverage into semi YoY growth in FY23 regulated/other 60% RoW markets 13% 27% Experience in Projects focused on working with lozenges, syrups, marquee global tablet
Slide 29: CDMO business - Developing New Concepts
CDMO business - Developing New Concepts Immunity Sleep disorder Motion sickness Wellness Oral thrush DEVELOPING NEW LOZENGES 28
Slide 30: H1 FY'23 Highlights
Delivering Value in Challenging Times H1 FY’23 Highlights Nov 2023 JB Pharma 29
Slide 31: Delivered a Successful H1 FY24
Delivered a Successful H1 FY24 30
Slide 32: JB Pharma: Outperforming the Nifty Pharma Index
JB Pharma : Outperforming the Nifty Pharma Index 31
Slide 33: Strong Balance Sheet & free cash-flow
JB Pharma - Strong Balance Sheet & free cash-flow Significant growth in the company’s Strong Cash Generation Net Worth • Operating cash flow at INR 4210 million in Net worth improved from INR 14380 H1 FY24 vs INR 2790 million in H1 FY23 million in FY20 to INR 27170 million in FY23 • JB Pharma approa
Slide 34: Sustainability
@® = Sustainability
Slide 35: Sustainability Report – FY 2022-2023
Sustainability Report – FY 2022 - 2023 Reporting Framework: Report prepared in accordance with the GRI 2021 Standards United Nations Sustainable Development Goals (UN SDGs) Reporting Period: This report covers the sustainability performance of the Company for the period 1st April 2022 till 31st Marc
Slide 36: JB Pharma – Looking ahead
JB Pharma – Looking ahead Growth objectives supported by lean organization structure and strong governance framework Domestic business to consistently outperform Continued growth momentum in International market growth driven by business Big brands becoming bigger Strong delivery in CDMO business ai
Slide 37: Thank you
Thank you www.jbpharma.com 36
J.B. Chemicals & Pharmaceuticals — Jefferies London Healthcare Conference 2023 on 6ix